Alector (ALEC) Cash from Investing Activities (2018 - 2026)
Alector's (ALEC) quarterly Cash from Investing Activities came in at $17.1 million in Q2 2026, down 69.28% year-over-year from $55.7 million in Q2 2025, and down 71.91% quarter-over-quarter from $60.9 million in Q1 2026.
Analysis
Alector (ALEC) Cash from Investing Activities (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Cash from Investing Activities for 9 consecutive years, with $17.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Investing Activities fell 69.28% year-over-year to $17.1 million in Q2 2026; TTM through Jun 2026 was $153.2 million, a 24.6% decrease from a year earlier, with the FY2025 full-year figure at $196.6 million, up 83.51% from the prior year.
- Cash from Investing Activities was $17.1 million for Q2 2026 at Alector, down from $60.9 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $88.7 million in Q1 2023 and troughed at -$225.8 million in Q2 2022.
- A 5-year average of $18.0 million and a median of $31.4 million in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities sank 499.04% in 2022 and soared 832.7% in 2023, its largest moves.
- Over 5 years, Cash from Investing Activities stood at $18.4 million in 2022, then retreated by 1.69% to $18.1 million in 2023, then soared by 129.11% to $41.4 million in 2024, then tumbled by 38.17% to $25.6 million in 2025, then slumped by 33.12% to $17.1 million in 2026.
- The last three Cash from Investing Activities figures came in at $17.1 million (Q2 2026), $60.9 million (Q1 2026), and $25.6 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -569.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.35 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -45.80 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -92.70 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 329.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -3.84 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | 17.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.12 Mn |
| Mar 31, 2026 | 60.95 Mn |
| Dec 31, 2025 | 25.60 Mn |
| Sep 30, 2025 | 49.54 Mn |
| Jun 30, 2025 | 55.72 Mn |
| Mar 31, 2025 | 65.74 Mn |
| Dec 31, 2024 | 41.40 Mn |
| Sep 30, 2024 | 40.35 Mn |
| Jun 30, 2024 | 37.15 Mn |
| Mar 31, 2024 | -11.77 Mn |
| Dec 31, 2023 | 18.07 Mn |
| Sep 30, 2023 | 16.96 Mn |
| Jun 30, 2023 | -21.82 Mn |
| Mar 31, 2023 | 88.70 Mn |
| Dec 31, 2022 | 18.38 Mn |
| Sep 30, 2022 | 60.53 Mn |
| Jun 30, 2022 | -225.82 Mn |
| Mar 31, 2022 | -12.11 Mn |
| Dec 31, 2021 | -146.75 Mn |
| Sep 30, 2021 | -69.05 Mn |